Latest:
Dr. Shinohara on Pairing SBRT With Immunotherapy in Prostate Cancer
Eric Shinohara, MD, MSCI, discusses the potential to combine stereotactic body radiotherapy with immunotherapy in prostate cancer.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Eric S. Winer, MD
Eric S. Winer, MD, is clinical director of Adult Leukemia at Dana-Farber Cancer Institute and an assistant professor of medicine at Harvard Medical School.
Latest:
Dr Winer on the Efficacy of Emavusertib in AML With FLT3 and Spliceosome Factor Mutations
Eric S. Winer, MD, discusses the efficacy of emavusertib in patients with relapsed/refractory AML harboring FLT3 and/or spliceosome factor mutations.
Eric Van Cutsem, MD, PhD
Latest:
Dr. Van Cutsem on Primary Findings from the SPOTLIGHT and GLOW Trials in Metastatic Gastric Cancer
Eric Van Cutsem, MD, PhD, discusses primary efficacy and safety findings from the phase 3 SPOTLIGHT and GLOW trials investigating the monoclonal antibody zolbetuximab in metastatic gastric cancer.
Eric Wisotzky, MD
Latest:
Rehabilitation Should Be Part of Cancer Treatment
Rehabilitation is medical care that cancer patients should expect and that it should be delivered by trained rehabilitation professionals: physiatrists, physical therapists, occupational therapists, or speech language pathologists.
Erica Bell, PhD
Latest:
Early Promise of Radiation Plus PCV in Patients With Low-Grade Glioma
Erica Bell, PhD, assistant professor-Clinical, Ohio State University Comprehensive Cancer Center, discusses a mutational analysis examining radiation therapy plus procarbazine, CCNU, and vincristine (PCV) as a potential treatment for patients with high-risk, low-grade glioma.
Erica DiNapoli
Erica DiNapoli is an Assistant Editor for
Latest:
Chasing Survival Benefit With Novel Systemic Strategies in Early-Stage NSCLC
Kaushal Parikh, MD, MBBS, highlights ongoing research exploring systemic approaches in early-stage non¬–small cell lung cancer and shares where future efforts are headed.
Erica L. Mayer, MD, MPH
Erica L. Mayer, MD, MPH, leads the Dana-Farber Breast Cancer in Pregnancy Program, overseeing the care of and research for of women diagnosed with breast cancer in pregnancy. She is the director of the Advanced Fellowships in Breast Oncology, and mentors students, residents, and fellows at Harvard Medical School and Dana-Farber.
Latest:
Dr Mayer on Efficacy Findings With Giredestrant Plus Everolimus in ER+/HER2– Advanced Breast Cancer
Erica Mayer, MD, MPH, discusses giredestrant plus everolimus vs physician’s choice of endocrine therapy plus everolimus in ER+, HER2-negative locally advanced or metastatic breast cancer.
Erik J. Blok, MD
Latest:
Dr. Blok on Results of Adjuvant Letrozole Study in Breast Cancer
Erik J. Blok, MD, Department of Medical Oncology at Leiden University Medical Center, discusses the duration of adjuvant endocrine therapy. Blok claims that there is no breast cancer survival benefit in extending adjuvant letrozole treatment from 2.5 to 5 years.
Erika N. Brown, BS, MS, PharmD
Latest:
Triple Receptor-Negative Breast Cancer: Current and Future Treatments
Breast cancer is the number one malignancy diagnosed in women in the United States. In 2009, it was estimated that more than 190,000 individuals would be diagnosed with breast cancer and approximately 40,000 would die from the disease.
Erika P. Hamilton, MD
Erika P. Hamilton, MD, is the director of Breast Cancer and Gynecologic Cancer Research at Sarah Cannon Research Institute.
Latest:
Dr Hamilton on First-Line Tucatinib-Based Maintenance in HER2+ Metastatic Breast Cancer
Erika P. Hamilton, MD, discusses data from HER2CLIMB-05 evaluating tucatinib plus trastuzumab/pertuzumab first-line maintenance in HER2-positive breast cancer.
Erika P. Hamilton, MD, Sarah Cannon Research Institute
Latest:
Insights in Breast Cancer, GI Malignancies at ASCO 2021: Drs Milind Javle and Erika Hamilton
OncLive sits down with Erika P. Hamilton, MD, and Milind Javle, MD, on the pivotal studies in breast cancer and gastrointestinal cancers, respectively, at the 2021 ASCO Annual Meeting.